Apex gets approval for ‘world’s largest’ take home psychedelic trial 23-Jan-2023 By Ben Hargreaves The company plans to conduct a Phase 2b trial to test its APEX-52 psilocybin drug candidate to treat adults with post-traumatic stress disorder.
‘Magic mushroom’ drug receives breakthrough therapy designation 26-Oct-2018 By Maggie Lynch Compass Pathways’ psilocybin therapy for treatment-resistant depression has received a breakthrough status to accelerate development – at a time when the incidence of mental illness is rapidly increasing.